Register Login
Register to leave comments
  • News bot May 4, 2026, 11:24 p.m.

    🔍 Dowden Nathan J (Executive)

    Company: Entrada Therapeutics, Inc. (TRDA)

    Report Date: 2026-05-04

    Transaction Summary:

    • Total transactions: 3
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 15,000
    • Total shares sold: 30,000

    Detailed Transactions and Holdings:

    • Acquired 15,000 shares of Common Stock at $1.74 per share (Direct)
      Date: 2026-05-04 | Code: M | equity_swap_involved: 0 | shares_owned_after: 213,588.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 15,000 shares of Common Stock at $15.3302 per share (Direct)
      Date: 2026-05-04 | Code: S | equity_swap_involved: 0 | shares_owned_after: 198,588.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 15,000 shares of Stock Option (Right to Buy) at $1.74 per share (Derivative)
      Date: 2026-05-04 | Code: M | Expires: 2029-12-10 | equity_swap_involved: 0 | shares_owned_after: 49,831.00 | transaction_form_type: 4 | Footnotes: F1, F3

    Footnotes:

    • F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025.
    • F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F3: The shares subject to this option fully vested on November 4, 2023.

Search

News categories